Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05648214 · ClinicalTrials.gov registry record · Phase 1

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Phase 1 study of Healthy Volunteers and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), sponsored by Regeneron Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
156
Enrollment target
6
Study locations

NCT05648214: Recruiting Phase 1 study of Healthy Volunteers and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), sponsored by Regeneron Pharmaceuticals.

NCT05648214 is a Phase 1 study of Healthy Volunteers and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 156 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (68% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05648214, a Phase 1 study of Healthy Volunteers and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
156 participants
Enrollment target
6
Study locations

Study Summary

This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug Administration (FDA) for any kind of treatment. This study consists of 3 parts. Part A is focused on healthy participants. Parts B and C of the study are focused on participants who are known to have MASLD and a specific variant of the PNPLA3 gene. The aim of the study is to see how safe, tolerable and effective the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug (Parts A, B and C) * How much study drug (Parts A, B and C) and study drug metabolites (byproduct of the body breaking down the study drug) (Parts B and C) are in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) (Part A, B and C) * Explore impact of Japanese ethnicity on safety and PK (Pharmacokinetics, or study of what the body does to the drug) of single doses of ALN-PNP over time (Part A) * How the study drug works to change liver fat content in MASLD (Part B and C) * Better understanding of the study drug and MASLD (Part B and C)

Conditions Studied

Healthy Volunteers Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Interventions

  • DRUG ALN-PNP
  • DRUG Placebo (PB)

Study Locations (6)

California

  • California Clinical Trials Medical Group - Glendale
  • Velocity Clinical research - Los Angeles

Florida

  • Genoma Research Group, Inc - Miami
  • Med Research of Florida, LLC - Miami

Louisiana

  • Tandem Clinical Research - Marrero

Texas

  • Pioneer Research Solutions - Houston

Trial Details

FieldValue
Enrollment Target 156 participants
Start Date 2022-12-27
Est. Completion 2027-08-10
Phase Phase 1
Regeneron Pharmaceuticals

280 total trials

What NCT05648214 shows while recruiting

NCT05648214 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (68% lower).

The record links to 2 conditions, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which ALN-PNP is the first listed.

NCT05648214 lists 6 locations in 4 states (California, Florida, Louisiana).

Frequently Asked Questions

What is clinical trial NCT05648214 about?

NCT05648214 is a clinical study titled "A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)". This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug Administration (FDA) for any kind of treatment. This study consists of 3 parts. Par...

What is the current status of trial NCT05648214?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 156 participants. The study started on 2022-12-27. Estimated completion is 2027-08-10.

What conditions does trial NCT05648214 study?

This clinical trial studies the following conditions: Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

What interventions are being tested in trial NCT05648214?

The interventions under investigation include: ALN-PNP (DRUG), Placebo (PB) (DRUG).

Who is sponsoring clinical trial NCT05648214?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05648214 being conducted?

This trial has 6 study locations across California, Florida, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05648214's enrollment target sits among peer trials

156 56th of 283 higher than 228 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03082755 · 156 participants · Phase 4

    Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

  • NCT04047628 · 156 participants · Phase 3

    Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

  • NCT04166877 · 156 participants · Phase 4

    Magnesium Infusion for Pain Management in Critically Ill Trauma Patients

  • NCT04533464 · 156 participants · Phase 2

    MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05648214

Source: ClinicalTrials.gov NCT05648214, the US trial registry maintained by the National Library of Medicine. NCT05648214 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.